Sun Pharma Advanced Research signs licensing deal with Biomodifying LLC

SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target

Mumbai: Sun Pharma Advanced Research Company Limited has entered into an agreement with Biomodifying LLC to exclusively license latter’s intellectual property, including all patents and patent applications, along with antibodies developed for multiple uses including for cancer.
Under the agreement, Biomodifying is eligible for an up-front payment, milestone payments
on pre-specified clinical, regulatory, and commercial milestones, as well as royalties on
sales. In addition, SPARC will pay Biomodifying a percentage of payments received for
sublicenses of the licensed IP.
“This is an important milestone for SPARC. The licensing of antibodies from Biomodifying will assist us in our endeavour to transition SPARC into a company focussed on novel treatment modalities, including bi-specific antibodies and antibody drug conjugates,” said Anil Raghavan, CEO of SPARC.